Form 4: BioLargo Director Christina Bray Receives Equity Compensation

BioLargo, Inc. Director Christina Bray was granted 93,750 options to purchase common stock at an exercise price of $0.20 as compensation for her board services.

Summary

• Christina Bray, a Director of BioLargo, Inc. (BLGO), acquired 93,750 options to purchase common stock.
• The options have an exercise price of $0.20 per share.
• The options become exercisable on June 30, 2025, and expire on June 30, 2035.
• These options were issued as payment for $18,750 in fees for her services on the board of directors for the most recently completed quarterly period.
• The grant was made pursuant to BioLargo's 2024 Equity Incentive Plan.
• Following this transaction, Christina Bray beneficially owns 1,053,731 shares of common stock directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. It's a routine insider transaction for compensation, which is generally expected. The issuance of options aligns director interests with shareholders, which is a positive governance practice. No negative implications are present.

Positives

• Issuance of options aligns director compensation with shareholder interests.
• The transaction is part of a pre-existing 2024 Equity Incentive Plan, indicating a structured compensation approach.

Future Outlook

No specific forward-looking statements or guidance are provided beyond the expiration date of the options.

Management Comments

• The option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically director compensation, which is common practice across industries to align management and director incentives with shareholder value. It does not provide broader industry trends.

Comparison to Industry Standards

• The compensation structure, involving stock options for board services, is a standard practice in corporate governance across various industries, including biotechnology and environmental services, where BioLargo operates.
• The specific value of $18,750 for quarterly board services and the grant of 93,750 options at a $0.20 exercise price would need to be compared against compensation benchmarks for directors in similar-sized companies within the environmental technology or water treatment sectors to assess its competitiveness and alignment with market rates. No specific comparable companies or projects are mentioned in the document to facilitate a direct comparison.

Corporate Governance

Stakeholder Impact

• Shareholders: The issuance of options to a director aligns their interests with shareholder value creation, as the options gain value if the stock price increases. It also represents a form of dilution if the options are exercised, though this is a standard aspect of equity compensation plans.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• No specific future actions or milestones are mentioned beyond the exercise and expiration dates of the options.

Key Dates

Keywords

BioLargo, BLGO, Christina Bray, stock options, equity incentive plan, director compensation, SEC Form 4, insider transaction, beneficial ownership